Casey Morrow, Ph.D.
Leader of the research team and professor emeritus
Department of Cell, Developmental and Integrative Biology
University of Alabama at Birmingham
MedicalResearch.com: What is the background for this study?
Response: The human gastrointestinal tract (GIT) contains several distinct physical environments within the stomach, small intestine (duodenum, jejunum, ileum) and colon that harbor complex microbial communities.
Changes in the fecal microbe composition have been described for Roux-en-Y gastric bypass (RYGB), the most effective and durable treatment for morbid obesity, and sleeve gastrectomy (SG). Continue reading →
Edward W. Hook, III, MD University of Alabama at Birmingham
Medicine / Infectious Diseases
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Zoliflodacin represents a new class of antibiotics (spiropyrimidinetriones) with in vitro activity against Neisseria gonorrhoeae, as well as other STD pathogens (Chlamydia trachomatis and Mycoplasma genitalium). Because of this promising data and the fact that the manufacturer (Entasis Pharmaceuticals) was willing to pursue the possibility of using this drug to treat gonorrhea, a Phase II trial was conducted which showed he drug to be 96% effective for genital or rectal infections. The drug was well tolerated as well making it a promising drug for gonorrhea treatment which might help to combat the increasing problem of antibiotic resistant gonorrhea.Continue reading →